Workflow
Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up
NTLAIntellia Therapeutics(NTLA) ZACKS·2025-05-09 17:25

Intellia Therapeutics (NTLA) incurred a loss of 1.10pershare(includingone−timeexpensesofchangeinfairvalueofinvestments)inthefirstquarterof2025,whichwasnarrowerthantheZacksConsensusEstimateofalossof1.10 per share (including one-time expenses of change in fair value of investments) in the first quarter of 2025, which was narrower than the Zacks Consensus Estimate of a loss of 1.26. In the year-ago quarter, the company had incurred a loss of 1.12pershare.Thecompany’stotalrevenuescurrentlycompriseonlycollaborationrevenues.Intelliareportedrevenuesof1.12 per share.The company’s total revenues currently comprise only collaboration revenues. Intellia reported revenues of 16.6 million for the first quarter of 2025. Revenues declined 42.6% on a year-over-year basi ...